Tag: Immunotherapy
ASCO: Ivonescimab Improves Progression-Free Survival in EGFR+ Lung Cancer
PFS benefit seen in most subgroups, including those whose disease progressed while receiving third-generation EGFR-TKIs
Neoadjuvant Nivolumab, Ipilimumab Safe for dMMR Colon Cancer
113 of 115 enrolled patients underwent timely surgery; two had surgery delayed by more than two weeks
Recommendations Developed to Prepare Patients for Oral Immunotherapy
76 statements specific to OIT preparatory procedures were included, as well as 71 on the consent information form
Guideline Issued for Management of Inhalant Allergies With Immunotherapy
Authors strongly recommend that clinician performing allergy skin testing or allergen immunotherapy be able to diagnose, manage anaphylaxis
Pembrolizumab Improves Event-Free Survival in Early NSCLC
For resectable early-stage NSCLC, improved event-free survival seen with pembrolizumab, regardless of N status, clinical stage, type of surgery
Secondary Primary Malignancies Rare After CAR T-Cell Immunotherapy
Projected five-year incidence of 15.2 and 2.3 percent for solid and hematologic malignancies after CAR T-cell immunotherapy
Cancer Vaccine Safe, Induces T-Cell Responses for KRAS-Mutated Tumors
Lymph node-targeting Amphiphile vaccine is safe; correlation seen for efficacy with T-cell response
End-of-Life Treatment With Immunotherapy Increasing for Patients With Cancer
Those treated at nonacademic or low-volume facilities have higher odds of initiating therapy within one month of death
MSI-H Colorectal Cancer Rarely Recurs After Immunotherapy Cessation
88 percent of 64 patients remained without disease progression after median of 22.6 months after stopping immunotherapy
ASH: Ibrutinib-Venetoclax Beneficial for Relapsed/Refractory Lymphoma
Improvement seen in progression-free survival for patients with relapsed/refractory mantle cell lymphoma